Sumitomo Dainippon Pharma Co (4506 JP): New Launches Ensure Post-Latuda Growth Trajectory
Sumitomo is on right track to alleviate patent cliff through new launches in the U.S. The company’s three new U.S. products have potential for...
604 Views
Neurocrine Biosciences: An Attractive Takeover Candidate with Potential >50% Upside.
FDA has accepted the New Drug Application (NDA) for Neurocrine Biosciences Inc (NBIX US) Valbenazine for the treatment of Tardive Dyskinesia (with...
576 Views